Precipio, Inc. (PRPO)

Market Cap	8.89M
Revenue (ttm)	17.41M
Net Income (ttm)	-3.00M
Shares Out	1.48M
EPS (ttm)	-2.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,960
Open	6.00
Previous Close	6.00
Day's Range	5.98 - 6.17
52-Week Range	4.31 - 7.30
Beta	1.42
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About PRPO

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

• Industry: Diagnostics & Research
• Sector: Healthcare
• CEO: Ilan Danieli
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: PRPO
• Website: https://www.precipiodx.com

Financial Performance

In 2023, Precipio's revenue was $15.20 million, an increase of 61.46% compared to the previous year's $9.41 million. Losses were -$5.85 million, -52.04% less than in 2022.